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Experimental Evidence
A number oflines ofevidence attest to the
ability of xenobiotic materials to affect
estrogen production (9). Ovariectomy,
which reduces endogenous hormones,
inhibits the progression of chemically
induced mammary tumors, whereas rein-
troduction of estrogen by implantation
stimulates tumor development. Moreover,
rat mammary cancers depend on both late
and early exposure to estrogen and pro-
lactin (11).
Experimental studies indicate that
estradiol metabolism proceeds primarily
via two mutually exclusive pathways, each
of which is affected by xenobiotic expo-
sures: pathway I to 2-hydroxyestrone (2-
OHEI), which has minimal estrogenic
activity and is nongenotoxic, or pathway II
to 16a-OHEI, a fully potent estrogen
which is also genotoxic (12). Breast cancer
risk appears to be linked with these two
pathways. Substances that elevate pathway
II or inhibit pathway I increase risk, where-
as those that inhibit pathway II or elevate
pathway I decrease risk. Thus, dimethyl
benzanthracene (DMBA), benzo[a]pyrene
(BaP), oncogenes, and tumor virus expo-
sure inhibit pathway I and also induce
mammary tumors (13). Dietary supple-
ments that increase pathway I, such as
indole-3-carbinol, also decrease mammary
tumor incidence (14), but those that
induce pathway II, such as alcohol, tend to
increase carcinogenic response (10,15). In
addition to affecting pathway II, alcohol
consumption has been shown to induce
P450IIE and decrease P4501A1, subfami-
lies of enzymes key to the metabolism of
other potential carcinogens (15).
As to the role ofdietary factors in estro-
gen production, a number of studies indi-
cate that both fat and fiber intake modu-
lates estrogen metabolism. Linoleic and
arachidonic acids increase pathway II (12).
A high-fiber diet, along with greater physi-
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Environmental Health Perspectives 372cal exercise, reduces enterohepatic resorp-
tion of fecal estrogens (16). Severe caloric
restriction results in major increases in
pathway I and reductions in pathway II
(1X.
A variety of in vitro and in vivo studies
have documented the estrogenicity ofsome
lipophilic, bioconcentrated xenobiotics;
that is, their ability to stimulate estrogen
and function as xenoestrogens (Table 1).
Estrogens promote breast cell proliferation
(18) and hypertrophy of other secondary
sex organs (19). Similar effects have been
observed in fish, birds, and wildlife (9).
Xenoestrogenic substances include several
lipophilic, persistent compounds for which
human, food chain, and wildlife exposures
have been widespread (20). These chemi-
cals include a number of chlorinated
organics, such as o,p'-DDT, an isomer of
the pesticide DDT, chlordecone, hep-
tachlor, and other pesticides, polychlori-
nated biphenyls (PCBs), triazine herbicide,
and a number of polycyclic aromatic
hydrocarbons (PAH), compounds derived
from petroleum products, fossil fuels, and
products of incomplete combustion. In
addition, some pharmaceutical agents such
as diethylstilbestrol (DES) are direct estro-
gens, and others, such as tamoxifen, mimic
estrogen in premenopausal women but
block estrogen in postmenopausal women
(21). Still other pharmaceuticals, such as
cimetidine, inhibit pathway I and stimu-
late breast cell proliferation (22). Animals
exposed to ambient levels of commonly
encountered compounds one at a time,
such as Aroclor 1254, a PCB, showed no
adverse effects. But animals dosed with
mixtures of ambient levels of commonly
encountered groundwater contaminants,
including PCBs and ubiquitous viruses,
developed a variety of adverse effects on
growth and reproduction (23).
A number of xenoestrogenic com-
pounds induce or promote breast cancer
experimentally (24). Primary carcinogene-
sis may also occur with other xenobiotics
because human breast epithelial and fibro-
blastic cells metabolize them to carcino-
genic electrophiles (25). Table 2 summa-
rizes the research on mammary carcino-
genicity ofseveral important, widely used
toxic substances. These indude o,p'-DDT,
some isomers ofPCB, benzene, and several
PAHs, including methylcholanthrene,
dibenz[ah]anthracence, and DMBA(26-28).
PAHs produce increased intracellular oxi-
dation and chromosomal breaks or gene
rearrangements (29).
Atrazine is ofspecial interest, as it is a
triazine herbicide that is one of the most
commonly used pesticides in the United
States today, and it is widely found in
groundwater (30). Atrazine is astable com-
pound that is retained in the abdominal fat
Table 1. Experimental evidence onthe estrogenicity ofsome chlorinated organics
Chemical
o,p-DDT
o,p'-DDT
Methoxychlor
Chlordecone
(kepone)
B-Hexachloro-
cyclohexane
PCBs
Kepone
(chlordecone),
heptachlor,
chlordane,
Aroclor 1221
Atrazine
In vivoevidence
Initiated implantation
and maintained
pregnancyin rats
Uterotropic (causes
increased uterine
weight) in rats
Initated implantation
and maintained
pregnancy in rats
Initiated implantation
and maintained
pregnancy in rats
Reference
Johnson etal.,
1992(67)
In vitroevidence
Inhibitsthe binding
of [3HJestradiol to
ratuterine
cytosolic estrogen
receptor
Welch etal., Inhibitsthe binding
1969(69) of13HJestradiol to
rat uterine cytosolic
estrogen receptor
Johnson etal.,
1992(67)
Johnson etal.,
1992(67)
Induction ofcystosolic
progesterone receptor;
redistribution of
estrogen receptors
Estrogen receptor
bindingto probes
Enhanced proliferative
potency in human
breastestrogen-
sensitive MCF7 cells
Hormone release
increased
Reference
Nelson,
1974(68)
Nelson,
1974(68)
Coosen and
Van Velsen,
1989(70)
Korach etal.,
1988(71)
Soto etal.,
1992(19)
Ghinea etal.,
1988(72)
Table2 Experimental evidence on mammary carcinogenesis ofsome chlorinated organics
Chemical Animal evidence Reference
Organochlorines
DDT Acceleratorofmammary Scribnerand
tumors in male micetreated Mottet, 1981 (73)
with 2-acetamidophenanthrene
Triazines Increased incidence ofmammary Pinteretal.,
Atrazine tumors in male rats 1990(32)
(750 ppmfor 126weeks)
Benzene Breastcancer, oral and respiratory routes Maltoni etal.,
1989(74)
Polycyclic aromatic hydrocarbons
Benzola]pyrene Mammarytumors, gastrointestinal route Huggins and Yang,
1962(75)
Dibenz[ahlanthracene Mammarytumors, gastrointestinal route Snell and Steard,
1962(76)
ofchickens for a week following 1 week of
feeding (31). It induces exceptionally rare
breast tumors in male animals and also
produces reproductive organ tumors (32)
andendocrinological effects.
Epidemiologic Evidence
Two recent epidemiologic studies have
highlighted the importance of pre-natal
exposures to estrogen for breast cancer.
One investigation found that women born
to mothers with pre-edampsia, and there-
fore lower estrogen levels during pregnan-
cy, had significandy reduced risks ofdevel-
oping breast cancer compared with con-
trols. In this same analysis, women born to
mothers with elevated estrogen during
pregnancy sustained an increased risk of
breast cancer that was not statistically sig-
nificant but may have biological impor-
tance (33).
A second study corroborates the role of
prenatal exposures to estrogen. Dizygotic
twins, whose mothers generallyhavehigher
levels of estrogens, have higher rates of
breast cancer. Among all twins, the odds
ratio associatedwith one ofthe twins being
male (1.54) was higher than those associat-
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Table 3. Case-control studies on chlorinated organics and breast cancer
Matching; No. ofcases/ Relative risk
Reference confounding controls Analytes (odds ratio)
Albertet al. 1982(77) None 8/7 DDT,aHCH,adieldrin,
(tumorvs. normal heptachlorepoxide
mammarytissue)
Wassermann etal., None 9/5 DDT,aDDD,a PCB,-
1976(78) HCH, dieldrin,
(tumor vs. normal heptachlorepoxide
mammarytissue)
Unger etal., 1984(48) No matching; age 14/21 DDE, PCB
(biopsy)
Unger etal., 1984(48) No matching; age 18/35 PCB
(autopsy)
Falck et al., 1992(49) No matching; age, 20/20 DDE,b DDT, PCB,b
height,weight, heptachlorepoxide,
smoking oxychlordane,
trans-nonachlor,
HCB, b-HCH
Mussalo-Rauhamaa No matching; age, 44/33 DDT, PCB, HCB,HCH,b 10.5(>0.1 ppm)
etal., 1990(50) parity,weight, heptachlorepoxide,
height, occupation, chlordane,
smoking, fish meals trans-nonachlor, PAH
Wolff et al., 1993(51) Age, menopausal 58/171 DDE,b PCB 4
status, day of cycle, (1Oth-90th
enrollmentdate, body percentile)
mass, age at
menarche, parity,
family history, past
benign disease,
lactation, smoking,
alcohol use, race
HCH, hexachlorocyclohexane; HCB, hexachlorobiphenyl.
aAlbert etal. (77) and Wasserman etal. (78) found differences between malignant and normal breasttissue for
these residues.
bAssociated with elevated risk.
ed with both twins being female (1.3) and
was highest in premenopausal women with
twin brothers (2.88) (34). This may be due
to the fact that developing, hormonally
affected organs in sisters of twin brothers
are exposed to relatively more circulating
prenatal estrogens than are twin sisters.
Prenatal imprinting may prime estrogen
receptors for subsequent response or pro-
vide irreversible programming ofthe distri-
bution of cytochrome P450s and other of
the terminal enzymes of the microsomal
and mitochondrial mixed-function oxi-
dase, electron transport chains.
Most of the known risk factors for
breast cancer, which at best account for
30% ofcases (2) are linked with total life-
time exposure to reproductive hormones
(35). Aside from genetics and radiation in
premenopausal breast cancer, these risk
factors include age, age at menarche,
menopause, and first full-term pregnancy,
total calorie intake, family history, height,
radiation exposure, and alcohol intake
(36). Artificial reduction of hormones by
ovariectomy before age 35 reduces human
breast cancer risk (36).
Diet influences estrogen production in
various ways. A diet of proportionally
higher total calories relative to body mass
can also alter the metabolism ofestrogen in
the gut and stimulate earlier onset of
menses. However, obese, premenopausal
women who are amenorrheic have reduced
risks of breast cancer, whereas obese post-
menopausal women have higher risks, pre-
sumably due to the ability of body fat to
enhance production of estrogens after
menopause when ovarian production of
estrogen diminishes rapidly (2). Severe
restriction of caloric intake appears to
reduce the risk ofbreast cancer (37), possi-
bly by delaying the onset ofmenses or oth-
erwise reducing total lifetime estrogen
exposure.
The role ofdietary fat for breast cancer
remains the subject of a lively debate and
inconsistent results. A meta-analysis of 12
case-control studies reported that the risk
of breast cancer increased with increasing
dietary fat and included some studies with
more than a twofold difference (38).
Others have found no such association
(39).
Direct epidemiologic evidence linking
chlorinated organics to breast cancer ranges
from suggestive geographic and cross-sec-
tional mortality analyses to case-control
studies. A recent analysis ofchemical plant
workers found more than a twofold in-
crease in breast cancer in female workers
exposed to dioxin contamination (40).
Elevated breast cancer rates were also
detected in an analysis of women exposed
to extensive environmental contamination
with PCBs in Japan (41). In contrast,
other studies have been negative (42,43).
Geographic and other large-scale analy-
ses have suggested a link between breast
cancer and PAH or chlorinated organic
compounds but have not involved any
direct measures of exposure (16). Signif-
icantly elevated rates ofbreast cancer have
been detected in one area of Minnesota
where water was contaminated with PAHs
(44,45). Women who work in the chemical
industry (46) or who live near hazardous
waste sites are also reported to have higher
rates of breast cancer (47). Another study
reported a temporal association between a
decrease in population exposure to chlori-
nated organics and a reduction in breast
cancer mortality rates (16).
As Table 3 reveals, most ofthe negative
analytic studies have involved fewer than
10 cases and have had only about a 30%
chance ofdetecting a twofold difference in
risk (48). Several more recent studies have
provided evidence that chlorinated organ-
ics are linked to breast cancer. In one
study, the breast fat ofwomen with cancer
at biopsy had about 40% more of some
chlorinated pesticides such as metabolites
of DDT and elevated levels of PCB (49).
About 50% more hexachlorocyclohexane
(50) was detected in pooled blood from
breast cancer cases compared to a pooled
reference group, controlling for age and
parity.
Further resolution ofthe role ofchlori-
nated organics comes from a well-designed
study that matched on several factors and
adjusted for a number of confounders.
This recent nested case-control study of58
prospectively gathered cases was drawn
from a cohort of 14,000 women. Women
at the 90th percentile of DDE in serum
had a fourfold greater risk ofbreast cancer
compared to those at the 10th percentile
(51). PCB levels also differed, but this dif-
ference was not statistically significant.
Two other case-control studies are also
germane involving ovarian cancer, which is
also hormonally mediated. A hospital-
based case-control study in Italy detected a
significant link between herbicides and
ovarian cancer but could not pinpoint spe-
cific exposures (52). A population-based
case-control study which provides better
characterization of exposure and controls
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for relevant reproductive risk factors notes
that women exposed to chlorinated organic
triazine herbicides through farmwork for
10 or more years have a relative risk of2.7
for ovarian cancer (53).
Hypothesis
A variety of experimental and human evi-
dence indicates that the greater the total
lifetime exposure to bioavailable estrogen,
the greater the risk for breast cancer. In
light of the pivotal role of estrogen, we
hypothesize that exposure to some xenoe-
strogens elevates endogenous hormone lev-
els, especially 16x-OHE1, which stimulate
breast cell proliferation and thereby induce
or promote breast cancer. Xenobiotic com-
pounds could alter bioactive estrogen or
progesterone in breast cancer cases or oth-
erwise induce mammary carcinogenesis
through the P450 enzymes. Those with
genetic susceptibility to breast cancer
might be exquisitely sensitive to the prolif-
erative effects ofxenoestrogenic substances
in the environment.
Xenoestrogenic compounds may work
through several estrogen-related mecha-
nisms or through other mechanisms unre-
lated to estrogen (Fig. 1). Environmental
chemicals may be directly estrogenic, as is
o,p'-DDT. Or they may alter estradiol
metabolism, or otherwise enhance the pro-
duction of 16a-OHE1 (pathway II) or
reduce the production of 2-OHEI (path-
way I), as occurs with some drugs such as
cimetidine. In addition, potentiating fac-
tors such as alcohol and fat may affect
estrogen hydroxylation. Other breast car-
cinogens appear to operate completely out-
side ofestrogen pathways as direct carcino-
gens. For example, fluoroscopic radiation
induces mammary carcinoma experimen-
tally and in humans, probably by direct
stimulation of proliferating ductal cells or
direct mutation ofstem cells.
Whatever the pathway to breast cancer,
genetic factors are ultimately involved in
the expression of this highly heterogenous
disease. Younger women are more affected
by inherited genetic factors, as hereditary
breast cancer accounts for 36% of breast
cancer cases ages 20-29, but only 1% of
cases over age 80 (54). In some families
with the rare, autosomal dominant Li-
Fraumeni syndrome (55), a high breast
cancer risk is due to the inheritance of a
specific cancer-predisposing mutation on
chromosome 17q2l (56,57). Results of a
recent population study suggest that more
than 6.5 women per 1000 with breast can-
cer are carriers of another inherited breast
cancer-predisposing mutation in a series of
codons on chromosome 17 (54).
As the proportion of inherited breast
cancer in the population is small (58),
most breast cancers result from acquired
mutations, possibly stemming from xenoe-
strogens or from environmental carcino-
gens that affect pathways other than estro-
gen. This hypothesis suggests that it is
important to study genetic-environmental
interactions to identify environmental fac-
tors that influence gene expression in the
great majority ofacquired mutations.
Two lines of evidence are pinpointing
the location of cancer-predisposing genes
on chromosome 17 in both inherited and
somatic mutations for breast cancer: gene
linkage studies in families with multiple
affected members and allelic composition
studies comparing tumors with normal tis-
sues for loss of heterozygosity (Fig. 1).
Two genes have recently been implicated
in the development of hereditary breast
cancer, the tumor-suppressor gene p53
(56-60), which maps to chromosome
17pl3.1, and the breast-cancer-suppressor
gene BRCA1 (61), which was originally
identified by linkage to the anonymous
DNA marker D17S74 at 17q21 (62) and
appears to be involved in the largest pro-
portion of inherited breast cancer. For
noninherited breast cancer, the role of
xenoestrogenic or xenobiotic exposures for
oncogene activation or gene suppression
needs to be carefully evaluated.
Discussion
How can we explain the fact that the gen-
eration of women who had their children
earlier in life and had more of them now
have higher rates of breast cancer? Ob-
viously, known risk factors do not com-
pletely account for breast cancer patterns
in industrialized countries (4). The great
preponderance of these factors, such as
early age ofmenses, late age ofmenopause,
reproductive history, and caloric intake rel-
ative to body weight, can be linked to total
lifetime exposure to bioavailable estrogen.
We need to identify xenobiotic factors that
directly or indirectly increase estrogen
exposure. A number ofstudies are suggest-
ed by this theory. Investigations ofpopula-
tions with differing rates of disease and
xenoestrogen exposures will permit us to
test this hypothesis, as will analyses of
archived materials from variedpopulations.
A major series of case-control studies in
countries with differing breast cancer rates
and chemical exposures should further
assess the role of xenoestrogenic materials
by assaying markers ofexposure to suspect
xenoestrogens and early markers ofbiolog-
ic effect. Special attention needs to be paid
to the mechanisms by which environmen-
tal exposures, including xenoestrogens,
might activate oncogenes or suppress other
genes, teasing out the interaction between
genetic susceptibility and environmental
factors. In addition, laboratory studies in
human cell culture and in vivo systems of
suspect xenoestrogenic materials should be
expanded to screen chemicals for estro-
genicity and to identify mechanisms by
which these substances could affect estro-
gen metabolism or otherwise promote the
development of breast cancer. Preliminary
in vitro work has found that several pesti-
cides enhance the production ofthe geno-
toxic pathway II, 16a-OHEI, and reduce
theyield ofthe nongenotoxic pathway I, 2-
OHEI.
The xenoestrogenic hypothesis offers a
possible resolution to several anomalies in
breast cancer research, including some
inconsistent results about dietary fat and
breast cancer. Fat per se may be less impor-
tant than xenoestrogenic contaminants in
fat at different stages in women's lives. As
to the postmenopausal period, one recent
study found that 4 years after treatment,
Figure 1. Hypothesized pathways to breast cancer. OHE1, hydroxyestrone; LOH, loss of heterozygosity.
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breast cancer recurred in postmenopausal
women with positive estrogen-responsive
receptors who ate diets high in fat, total fat
intake, and saturated and polyunsaturated
fats, as assessed at time of diagnosis (63).
We need to determine whether bioaccu-
mulated lipophilic, xenoestrogenic sub-
stances, such as PAHs and chlorinated
organics, are elevated in these women, as
well as whether saturated animal fats bio-
concentrate higher levels of such com-
pounds than do polyunsaturated vegetable
fats.
This hypothesis also may account for
one ofthe discrepancies in cancer that was
first noted by the distinguished Danish
researcher Clemmensen. Commonly re-
ferred to as Clemmensen's hook, the dis-
crepancy occurs in the relationship be-
tween age and breast cancer incidence for
several countries. Incidence of breast can-
cer rises monotonically with age up to
about age 45, after which the rate of
increase forms a hook and levels off or
declines for about 10 years and then
resumes an increasing, but more modest
slope (64). The ages of this plateau corre-
spond to the period of perimenopause,
when the ovaries begin to produce less
estrogen and progestin. It is tempting to
speculate that the renewed surge in breast
cancer after menopause, especially in obese
women, might be linked with xenoestro-
gens and with the production of endoge-
nous estrogens, which would be greatest in
those with proportionally more body fat.
A recent series of studies on the possi-
ble link of environmental hormones with
male reproductive disorders bears mention
(65). Reported disorders ofthe male repro-
ductive tract, including reduced sperm
counts and testicular cancer, have increased
over the past several decades (66). Could
prenatal exposures to xenoestrogens be
involved? Evidence from a number of
fields points to the profound importance
ofendogenous and xenobiotic materials for
the production of estrogen and other hor-
mones. Future research will need to span
disciplines to discern the extent to which
human activities affect hormones through-
out ourlives.
With respect to breast cancer, most of
the confirmed risk factors, which relate to
reproductive behavior and dietary factors,
are not easily changed by social policy.
Many of the proposed interventions to
reduce breast cancer involve the lifelong
use of pharmaceutical agents or the advo-
cacy ofradical changes in diet, lifestyle, or
even reproductive behavior. As to the latter
point, a generation of women that has
struggled long for reproductive freedom is
unlikely to embrace suggestions that con-
strain reproductive choices. Research to
pinpoint preventable causes of breast can-
cer is critically needed. Ifxenoestrogens do
play a role in breast cancer, reductions in
exposure will provide an opportunity for
primary prevention ofthis growing disease.
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